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Abstract
BioPAX (Biological Pathway Exchange) is a standard language to represent biological pathways 
at the molecular and cellular level. Its major use is to facilitate the exchange of pathway data 
(http://www.biopax.org). Pathway data captures our understanding of biological processes, but its 
rapid growth necessitates development of databases and computational tools to aid interpretation. 
However, the current fragmentation of pathway information across many databases with 
incompatible formats presents barriers to its effective use. BioPAX solves this problem by making 
pathway data substantially easier to collect, index, interpret and share. BioPAX can represent 
metabolic and signaling pathways, molecular and genetic interactions and gene regulation 
networks. BioPAX was created through a community process. Through BioPAX, millions of 
interactions organized into thousands of pathways across many organisms, from a growing 
number of sources, are available. Thus, large amounts of pathway data are available in a 
computable form to support visualization, analysis and biological discovery.
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Introduction
Molecular biology research has yielded detailed knowledge of biomolecular components 
and their interactions. Increasingly powerful technologies, including genome-wide 
molecular measurements, have accelerated the progress towards a complete map of 
molecular interaction networks in cells and between cells of key organisms. A single person 
can no longer memorize these maps, therefore, they must be represented in a form suitable 
for computer processing and storage and made easily available to scientists via software 
systems. Accordingly, the BioPAX (Biological Pathway Exchange) project aims to facilitate 
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knowledge representation, systematic collection, integration and wide distribution of 
pathway data from heterogeneous information sources and thereby, their incorporation into 
distributed biological information systems that support visualization and analysis.
Goal: toward complete representation of basic cellular processes
Biology has come a long way since the Boehringer-Mannheim wall chart of metabolic 
pathways1 and the Nicholson Metabolic Map2. Since then, a number of groups have 
developed methods and databases for organizing pathway information3-16, but only recently 
collaborated as part of the BioPAX project to develop a generally accepted standard way of 
representing these pathway maps. Complete molecular process maps must include all 
interactions, reactions, dependencies, influence and information flow between pools of 
molecules in cells and between cells. For ease of use and simplicity of presentation, such 
network maps are often organized in terms of sub-networks or pathways. Pathways are 
models that biologists have delineated within the entire cellular biochemical network that 
help us describe and understand specific biological processes. Thus, a useful definition of a 
pathway is a set of interactions between physical or genetic cell components, often 
describing a cause-and-effect or time-dependent process, which explain some observable 
biological function. How do we represent these pathways in a generally accepted and 
computable form?
Challenge: strong growth of pathway databases
The total volume of pathway data mapped by biologists and stored in databases has entered 
a rapid growth phase17, similar to the rapid expansion of biological sequence data after the 
introduction of automated sequencing technology. The number of pathway and molecular 
interaction related online resources has grown from 190 in 2006 to 325 in 2010, a 70% 
increase17. In addition, molecular profiling methods, such as RNA profiling using 
microarrays or protein quantification using mass spectrometry, provide large amounts of 
information about the dynamics of cellular pathway components and increase the power of 
pathway analysis techniques18,19. However, this growth poses a formidable challenge for 
pathway data collection and curation as well as for database, visualization and analysis 
software, as these data are often fragmented.
Impediment: fragmentation of pathway databases
The principal motivation for building pathway databases and software tools is to facilitate 
qualitative and quantitative analysis and modeling of large biological systems using a 
computational approach. Over 300 pathway or molecular interaction related data 
resources17 and many visualization and analysis software tools3,20-22 have been 
developed. Unfortunately, most of these databases and tools were originally developed to 
use their own pathway representation language, resulting in a heterogeneous set of resources 
that are extremely difficult to combine and use. This has occurred because many different 
research groups, each with their own system for representing biomolecules and their 
interactions in a pathway, work independently to collect pathway data recorded in the 
literature (estimated from text-mining projects23 to be present in at least 10% of the over 20 
million articles currently indexed by PubMed). As a result, researchers waste much time 
collecting information from different sources and converting its representation from one 
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system to another. They may pay substantial opportunity cost as a result of pathway data 
fragmentation. For instance, visualization and analysis tools developed for one pathway 
database cannot be reused for others, making software development efforts more expensive. 
The situation currently resembles biologists assembling a multi-dimensional puzzle, with 
thousands of pieces, each one created and shared ad hoc. It is, therefore, imperative to 
develop computational methods to cope with both the magnitude and fragmented nature of 
this rapidly expanding and exceedingly valuable pathway information. While independent 
research efforts are needed to find the best ways to represent pathways, community 
coordination and agreement on one or a few standard sets of semantics is necessary to be 
able to efficiently integrate pathway data from multiple sources on a large scale.
Requirement: a shared language for pathways
A common, inclusive and computable pathway data language is necessary to share 
knowledge about pathway maps and to facilitate integration and use for hypothesis testing in 
biology24. A shared language facilitates communication by reducing the number of 
translations required to exchange data between multiple sources (Figure 1). Developing such 
a representation is challenging due to the large variety of pathways in biology and the 
diverse uses of pathway information. Pathway representations frequently use abstractions for 
metabolic, signaling, gene regulation, protein interaction and genetic interaction and these 
serve as a starting point toward a shared language25. Also, several variants of this common 
language may be required to answer relevant research questions in distinct fields of biology, 
each covering unique levels of detail addressing different uses, but these should be rooted on 
common principles and must remain compatible.
Implementation: the BioPAX biological pathway exchange language
BioPAX was developed to address these challenges. We have developed BioPAX as a 
shared language to facilitate communication between diverse software systems and to 
establish standard knowledge representation of pathway information. BioPAX supports 
representation of metabolic and signaling pathways, molecular and genetic interactions and 
gene regulation. Relationships between genes, small molecules, complexes and their states 
(e.g. post-translational protein modifications, mRNA splice variants, cellular location) are 
described, including the results of events. Details about the BioPAX language are available 
in online documentation at http://www.biopax.org. The BioPAX language provides a set of 
terms, with associated descriptions, to represent many aspects of biological pathways and 
their annotation. It is implemented as an ontology, a formal system of describing knowledge 
(Box 1) that helps structure pathway data so that it is more easily processed by computer 
software (Figure 2). It provides a standard syntax used for data exchange that is based on 
OWL (Web Ontology Language) (Box 1). Finally, it provides a validator that uses a set of 
rules to verify whether a BioPAX document is complete, consistent and free of common 
errors. BioPAX is the only community standard for biological pathway exchange to and 
from databases, but coordinates with other standards in related areas (Figure 6).
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Example of a pathway in BioPAX
Pathway models described by biologists are generally expressed in scientific language and 
as network diagrams. An example is the AKT signaling pathway, important in regulating 
proliferation in many eukaryotic cells and often deregulated in cancer26,27. The AKT 
pathway is a cell surface receptor activated signaling cascade that transduces signals from 
the outside to the inside of a cell via a series of molecular binding and protein post-
translational regulation events. These include protein-protein interactions and protein kinase 
mediated phosphorylation events that successively activate downstream kinases to 
phosphorylate additional proteins and activate or inhibit molecular interactions. The 
activated pathway eventually results in activation of multiple transcription factors, which 
turn on sets of genes to promote cell survival. A typical AKT signaling pathway diagram 
with associated text description can only be interpreted by people, and not computationally. 
By representing the pathway using the BioPAX language (Figure 3), it can also be 
interpreted by computer software and made available for numerous uses, such as pathway 
analysis of gene expression data. Representing a pathway using the BioPAX language 
sometimes necessitates being more explicit to avoid capturing inconsistent data. For 
instance, the typical notion of an ‘active protein’ is context dependent, as the same molecule 
could be active in one cellular context, such a cellular compartment with a set of potential 
interacting molecules, and inactive in another context. Thus, capturing the specific 
mechanism of activation, such as phosphorylation modification, is usually required, and the 
presence of downstream events that include the modified form signifies that the molecule is 
active. Interactions where the mechanism of action is unknown can also be specified.
What does BioPAX include?
BioPAX covers all major concepts familiar to biologists studying pathways, including 
metabolic and signaling pathways, gene regulatory networks and genetic and molecular 
interactions (Table 3). The BioPAX language is distributed as an ontology definition (Figure 
4) with associated documentation, a validator and other software tools (Table 1). Frequently 
used pathway abstractions in multiple pathway databases and software are supported as 
follows:
• Metabolic pathways are described using the enzyme, substrate, product 
abstraction28 where substrates and products of a biochemical reaction are often 
small molecules. An enzyme, often a protein, catalyzes the reaction and inhibitors 
and activators can modulate the catalysis event.
• Signaling pathways involve molecules and complexes participating in biochemical 
reactions, binding, transportation and catalysis events (Figure 3)5,9,29-31. 
Molecular states (cellular location, covalent and non-covalent modifications as well 
as sequence fragments) and generic molecules (such as the homologous family of 
Wnt proteins) may be described.
• Gene regulatory networks involve transcription and translation events and their 
control12,14. Transcription, translation and other template-directed reactions 
involving DNA or RNA are captured in a template reaction in BioPAX, which 
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maps a template to its encoded products (e.g. DNA to mRNA). Multiple sequence 
regions on a single strand of the template, such as promoters, terminators, open 
reading frames, operons and various reaction machinery binding sites, are active in 
a template reaction. Transcription factors (generally proteins and complexes), 
microRNAs and other molecules, participate in a template reaction regulation 
event.
• Molecular interactions, notably protein-protein32-36 and protein-DNA 
interactions37, involve two or more physical entities. BioPAX follows the standard 
representation scheme of the Proteomics Standards Initiative Molecular Interaction 
(PSI-MI) format38.
• Genetic interactions occur between two genes when the phenotypic consequence of 
perturbing both genes is different than expected given the phenotypes of each 
single gene perturbation39. BioPAX represents this as a pair of genes that 
participate in a genetic interaction measured using an observed phenotype.
The first three pathway abstractions are process-oriented. They imply a temporal order and 
can be thought of as extensions of the standard chemical reaction pathway notation to 
accommodate biological information. Molecular and genetic interactions, however, imply a 
static network of connections among system components instead of the temporally ordered 
process of reactions that defines a metabolic or signaling pathway. BioPAX supports 
combining these different types of data into a single model that is useful to gain a more 
complete view of a cellular process.
BioPAX provides many additional constructs, not shown in Figure 4, that are used to store 
extra details, such as database cross-references, chemical structure, experimental forms of 
molecules, sequence feature locations and links to controlled vocabulary terms in other 
ontologies (Supplementary Figure S1). BioPAX reuses a number of standard controlled 
vocabularies defined by other groups. For example, Gene Ontology40 is used to describe 
cellular location, PSI-MI vocabularies38 are used to define evidence codes, experimental 
forms, interaction types, relationship types and sequence modifications, and Sequence 
Ontology41 is used to define types of sequence regions, such as a promoter region on DNA 
involved in transcription of a gene. Other useful controlled vocabularies can be referenced, 
such as the molecule role ontology42.
BioPAX defines additional semantics that are currently only captured in documentation. For 
instance, physical entities represent pools of molecules and not individual molecules, 
corresponding to typical semantics used when describing pathways in textbooks or 
databases. A molecular pool is a set of molecules in a bounded area of the cell, thus it has a 
concentration. Pools can be heterogeneous and can overlap, as in the case of a protein 
existing in multiple phosphorylation states.
BioPAX also defines a range of constructs that are represented as ontology classes. Some of 
these represent biological entities, such as proteins, and are organized into classes that 
conceptualize the pathway knowledge domain. Others are used to represent annotations and 
properties of the database representation of biological entities. For instance, BioPAX 
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provides xref classes to represent different kinds of references to databases that can be useful 
for data integration. These are represented as subclasses of utility class for convenience. A 
future version of BioPAX would ideally capture these semantics and structure these 
concepts more formally.
Uses of pathway information in BioPAX language
Once pathway data is translated into a standard computable language such as BioPAX, it is 
easier for software to access it and thereby support browsing, retrieval, visualization and 
analysis by biologists (Figure 5). This enables efficient re-use of data in different ways 
avoiding the time-consuming and often frustrating task of translating it between formats 
(Figure 1). Additionally, it enables uses that would be impractical without a standard format, 
such as those dependent on combining all available pathway data.
BioPAX can be used to help aggregate large pathway datasets by reducing the required 
collection and translation effort, for instance using software such as cPath43. Typical 
biological queries, such as “What reactions involve my protein of interest?” generate more 
complete answers when querying these larger pathway datasets. Another frequent use is to 
find pathways that are active in a particular biological context, such as a cell state, as 
determined by a genome-scale molecular profile measurement. For instance, pathways with 
multiple differentially expressed genes, as measured by DNA microarrays, may be 
transcriptionally active in one biological condition and not in another. Functional genomics 
and pathway data can be imported into software and combined for visualization and analysis 
to find interesting network regions. A typical workflow involves overlaying molecular 
profiling data, such as mRNA transcript profiles, on a network of interacting proteins to 
identify transcriptionally active network regions, which may represent active pathways44. A 
number of recent papers have used this pathway analysis workflow to highlight genes and 
pathways that are active in specific model organisms or diseased tissues, such as breast 
cancer, using gene and protein expression, copy number variants (CNVs) and 
SNPs19,44-49. BioPAX has been used in a number of these studies to collect and integrate 
large amounts of pathway information from multiple databases for analysis. For instance, 
protein expression data was combined with pathway information to highlight the importance 
of apoptosis in a mouse model of heart disease50. Multiple groups have found that tumor 
associated mutations are significantly related by pathway information47,48. And recently, in 
a study of rare CNVs in 996 autism spectrum disorder affected individuals, a core set of 
neuronal development related pathways were found to link dozens of rare mutations to 
autism that were not significantly linked to the disorder on their own by traditional single-
gene association statistics49. These studies highlight the importance of pathway information 
in explaining the functional consequence of mutations in human disease. BioPAX pathway 
data can also be converted into simulation models, for instance using differential 
equations51 or rule-based modeling languages52, to predict how a biological system may 
function after a gene is knocked-out.
BioPAX is useful for exchanging information among and between data providers and 
analysis software. Pathway database groups can share the effort of pathway curation by 
making their pathways available in BioPAX format and exchanging them with others. For 
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example, Reactome8 BioPAX formatted pathways are imported by the NCI/Nature Pathway 
Information Database (PID)9. Data providers can use existing BioPAX enabled software to 
add useful new features to their systems. For example, the Cytoscape network visualization 
software20 can read and display BioPAX formatted data as a network. The Reactome group 
used this feature to create a pathway visualization tool for their website. Because Reactome 
data were available in BioPAX format, and Cytoscape could already read BioPAX format, 
this new feature was easy to implement.
The Paxtools Java programming library for BioPAX has been developed to help software 
developers readily support the import, export and validation of BioPAX formatted data for 
various uses in their software (http://www.biopax.org/paxtools/). Using Paxtools and other 
tools, a range of BioPAX-aware software has been developed, including browsers, 
visualizers, querying engines, editors and converters (Table 2). For instance, the ChiBE and 
VisANT pathway visualization tools read BioPAX format22 and the WikiPathways 
website53, a community wiki for pathways, is working on using BioPAX to help import 
pathways from numerous sources, including manually edited pathways from biologists. The 
Pathway Tools software21 and CellDesigner pathway editor54 are developing support for 
BioPAX-based data exchange. In addition, tools for the storage and querying of Resource 
Description Framework (RDF - http://www.w3.org/RDF/) datasets, generated within the 
Semantic Web community, can be used to effectively process BioPAX data.
What is not covered?
The BioPAX language uses a discrete representation of biological pathways frequently used 
in databases, the literature and textbooks. Dynamic and quantitative aspects of biological 
processes, including temporal aspects of feedback loops and calcium waves, must also be 
considered in a complete pathway map. BioPAX does not support this, but coordinates with 
the SBML and CellML mathematical modeling languages55,56 and a growing software 
toolset supporting biological process simulation57 which cover these aspects. Detailed 
information about experimental evidence supporting a pathway map is useful for 
recognizing the relative levels of support for different pathway aspects. This information is 
only included in BioPAX for molecular interactions, because that was already defined by the 
Proteomics Standards Initiative Molecular Interactions (PSI-MI) language58 and it was 
reused. The BioPAX workgroup makes use of PSI-MI controlled vocabularies and other 
concepts and coordinates with the PSI-MI workgroup to build these vocabularies in areas of 
shared interest, such as genetic interactions. Although BioPAX does not aim to standardize 
how pathways are visualized, work is coordinated with the Systems Biology Graphical 
Notation (SBGN, http://sbgn.org) community to ensure that SBGN can be used to visualize 
BioPAX pathways. Currently, most BioPAX concepts can be visualized using SBGN 
process description (PD) and SBGN activity flow (AF) diagrams and a mapping of BioPAX 
to SBGN entity relationship (ER) diagrams is under development. BioPAX development is 
coordinated with the above standardization efforts to ensure complementarity and 
compatibility. For instance, BioPAX uses controlled vocabularies developed by PSI-MI and 
can be used to annotate SBML and CellML models (Figure 6). BioPAX aims to be 
compatible with these and other efforts, so that pathway data can be transformed between 
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alternative representations when needed. For instance, PSI-MI to BioPAX and SBML to 
BioPAX converters are available (Table 2).
How does the BioPAX community work?
While BioPAX facilitates communication of current knowledge, it is challenging for all 
knowledge representation efforts to anticipate new forms of information. As new types of 
pathway data and new knowledge representation languages and tools become available, the 
BioPAX language must evolve through the efforts of a community of scientists that includes 
biologists and computer scientists.
BioPAX is developed via community consensus among data providers, tool developers and 
pathway data users. More than 15 BioPAX workshops have been held since November 
2002, attended by a diverse set of participants. Incremental versions (or levels) of the 
BioPAX language were progressively developed at these workshops to focus the group’s 
efforts on attainable intermediate goals. Broader input came from mailing lists and a 
community wiki. Community members participated in developing functionality they were 
interested in, which was integrated into specific levels (See Supplementary Table S1). Level 
1 supports metabolic pathways, Level 2 adds support for molecular interactions and post-
translational protein modifications by integrating data structures from the PSI-MI format, 
and Level 3 adds support for signaling pathways, molecular state, gene regulation and 
genetic interactions (Table 3). It is anticipated that newer BioPAX levels replace older ones, 
so use of the most recent BioPAX Level 3 is currently recommended. To ease the burden on 
users and developers, BioPAX aims to be backwards compatible where practical. Level 2 is 
backwards compatible with Level 1, however Level 3 involved a major redesign that 
necessitated breaking backwards compatibility. This said, many core classes have remained 
compatible with previous levels since Level 1 and software is provided for updating older 
BioPAX pathways to Level 3 (via Paxtools). All BioPAX material (Table 1) is made freely 
available under open source licenses via a central website (http://www.biopax.org) in order 
to encourage broad adoption. The database and tool support (Table 2) of a common 
language aids the creation, analysis, visualization and interpretation of integrated pathway 
maps.
In addition to the creation of a shared language for data and software, the process of 
achieving community consensus spurs innovation in the field of pathway informatics. 
Community discussion helps resolve technical knowledge representation issues faced by 
many data providers and users and facilitates the convergence to common terminology and 
representation. Solutions are discovered in independent research groups and incorporated in 
new data models and community best practices, which then enable identification of new 
issues. Thus, community workshops support a positive feedback cycle of knowledge sharing 
that has led to an accepted BioPAX language and development of better software and 
databases. We expect this to continue and to support new scientific uses of pathway 
information, motivated by end user access to valuable integrated pathway information and 
efficiency gain for database and software development groups. This will especially benefit 
new pathway databases and software tools that adopt standard representation and software 
components from the start.
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Future community goals
The BioPAX shared language is a starting point on the path to developing complete maps of 
cellular processes. Additional near and long-term goals remain to be realized to enable 
effective integration and use of biological pathway information, as described below.
Data collection
Data must be collected and translated to a standard format for it to be integrated. This 
process is underway, as the descriptions of millions of interactions in thousands of pathways 
across many organisms from multiple databases are now available in BioPAX format. 
However, vast amounts of pathway data remain difficult to access in the literature and in 
databases that don’t yet support standard formats. Increasing use of standards requires 
promoting and supporting data curation teams and automating more of the data collection 
process using software. Easy to use tools for tasks like pathway editing must also be 
developed so that biologists can share their data in BioPAX format without substantial 
investment. Ideally, appropriate software would allow authors to enter data directly in 
standard formats during the publication process, to facilitate annotation and normalization 
by curators before incorporation into databases for use by researchers53.
Validation and best practice development
To aid data collection, community best practice guidelines and rules must be developed, led 
by major data providers, to help diverse groups use BioPAX consistently when multiple 
ways of encoding the same information exist. This will enable data providers to benefit from 
automatic syntactic and semantic validation of their data so they can ensure they are sharing 
data using standard representation and best practices59,60. Data collection and automatic 
validation will facilitate convergence to generally accepted biological process models.
Semantic integration
Multiple models of the same biological process may usefully co-exist. Ideally, different 
models could be compared for analysis and hypothesis formulation. However, comparison is 
difficult because the same concept can be represented in multiple ways due to use of 
multiple levels of abstraction (such as the hRas protein versus the Ras protein family), use of 
different controlled vocabularies, data incompleteness or errors. Future research needs to 
develop semantic integration solutions that recognize and aid resolution of conflicts.
Visualization
Pathway diagrams are highly useful for communicating pathway information, but their 
automatic construction, in a biologically intuitive way, from pathway data stored in BioPAX 
is a major challenge. The SBGN pathway diagram standardization effort provides a starting 
point towards achieving this goal (Figure 3). Intuitive and automatically drawn biological 
network visualizations may one day replace printed biology textbooks as the primary 
resource for knowledge about cellular processes.
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Language evolution
As uses of pathway information and technology evolve, so must the BioPAX language. For 
instance, future BioPAX levels should capture cell-cell interactions, be better at describing 
pathways where sub-processes are not known or need not be represented, more closely 
integrate third-party controlled vocabularies and ontologies to ease their use and better 
encode semantics for easier data validation and reasoning.
Many groups within the BioPAX community, including most pathway data providers and 
tool developers, are working to achieve the above goals. For instance, Pathway Commons 
(http://www.pathwaycommons.org) aims to be a convenient single point of access for all 
publicly accessible pathway information and the WikiPathways project (http://
www.wikipathways.org/) seeks to enable pathway curation by individuals53. Also, the 
semantic web community is developing a set of technologies that promise to ease the 
integration of information dispersed on the World Wide Web (WWW)61. These 
technologies will aid pathway data integration, since BioPAX is compatible with them 
through use of the W3C standard Web Ontology Language, OWL. All of the above research 
and development activities support the vision of data providers sharing computable maps of 
biological processes in a standard format for convenient use by a community of pathway 
researchers.
Box 1
What is an ontology?
An ontology is a formal system for representing knowledge62. Formal representation is 
required for computer software to make use of information. Formal knowledge systems 
have been used in science for thousands of years, for example, Aristotle’s representation 
of the basic elements of all things (the five elements Fire, Earth, Air, Water and Ether). 
Well known modern examples include organism taxonomies63 or the Gene Ontology64. 
A formal representation allows for consistent communication of knowledge between 
individuals or computer systems and helps manage complexity in information processing 
as knowledge is broken down into clear concepts that can be considered independently. 
Ontologies also enable integration of knowledge between independent resources linked 
on the World Wide Web (WWW). Such linked, structured data form the basis of the 
semantic web, an extension of the WWW that promises improved information 
management and search capability61. Representing and sharing knowledge using 
ontologies is simplified by availability of the standard web ontology language (OWL) 
(http://www.w3.org/TR/owl-features/). Tools to edit OWL, such as Protégé65, have been 
developed by the Semantic Web community and adopted in the life sciences.
An ontology is composed of classes, properties (representing relations) and restrictions 
and is used to define individuals (instances of classes, also known as objects) and values 
for their properties. Classes (also known as concepts, types) are often arranged into a 
specialization hierarchy (or taxonomy) where child classes are more specific than, and 
inherit the properties of, parent classes. For example, in BioPAX, the Biochemical 
Reaction class is a ‘subclass of’ the Conversion class. Classes may have properties (also 
known as fields, attributes or slots), which express possible relations to other classes (i.e. 
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the may have values of specific types). For example, a Small Molecule is related to the 
Chemical Structure class by the property structure. Restrictions (also known as 
constraints) define allowable values and connections within an ontology. For example, 
Molecular Weight must be a positive number. Individuals are instances of classes where 
values occupy the properties of those instances. BioPAX defines the classes, properties 
and restrictions required to represent biological pathways and leaves creation of the 
individuals to users (data providers and consumers). Advantages of implementing 
BioPAX using OWL are that both the ontology and the individuals and values can be 
stored in the same XML-based format, which makes data transmission easier. Also, 
OWL is a standard ontology language that is supported by useful software tools for 
editing, transmitting, querying, reasoning and visualizing.
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Figure 1. 
BioPAX is a shared language for biological pathways. BioPAX reduces the effort required 
to efficiently communicate between pathway users, databases and software tools. Without a 
shared language, each system must speak the language of all other systems in the worst case 
(black lines). With a shared language, each system only needs to speak that language 
(central red box).
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Figure 2. 
BioPAX enables computational data gathering, publication and use of information about 
biological processes. Traditional pathway information processing: Observations considering 
prior models published as text and figures. Computable pathway information processing: 
Scientist’s description represented using formal, computable framework (ontology) 
published in a computer software readable format for analysis by scientists.
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Figure 3. 
The AKT pathway as represented by a traditional method (top left, from http://
www.biocarta.com), a formalized SBGN diagram (http://www.sbgn.org 84) (left), and using 
the BioPAX language (right). An important advantage of the BioPAX representation is that 
it can be interpreted by computer software and used in multiple ways, including automatic 
diagram creation, information retrieval and analysis. Online documentation at http://
www.biopax.org contains more details about how to represent diverse types of biological 
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pathways. Actual samples of pathway data in BioPAX OWL XML format are available in 
Supplementary Tables S2 and S3.
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Figure 4. 
High-level view of the BioPAX ontology. Classes are shown as boxes and arrows represent 
inheritance relationships. The three main types of classes in BioPAX are colored, Pathway 
(red), Interaction (green) and PhysicalEntity and Gene (blue). For brevity, only the 
properties of the Protein class are shown as an example at the top right. Refer to BioPAX 
documentation at http://www.biopax.org for full details of all classes and properties.
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Figure 5. 
Example uses of pathway information in BioPAX format. Red colored boxes or lines 
indicate use of BioPAX.
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Figure 6. 
The relationship among popular standard formats for pathway information. BioPAX and 
PSI-MI are designed for data exchange to and from databases and pathway and network data 
integration. SBML and CellML are designed to support mathematical simulations of 
biological systems and SBGN represents pathway diagrams.
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Table 1
What is included in BioPAX
Ontology specification Web Ontology Language (OWL) XML file,
developed using free Protégé ontology editor
software65.
Language documentation Explanation of BioPAX entities, example
documentation, best practice recommendations,
use cases and instructions for carrying out
frequently used technical tasks.
Example files Example files for biochemical pathway, protein
and genetic interaction, protein phosphorylation,
insulin maturation, gene regulation, generic
molecules in OWL XML.
Graphical representation Recommendations for graphical representation
using Systems Biology Graphical Notation
(SBGN) as a guide.
Paxtools software Java programming library supporting
import/export, conversion, validation. Can be
used to add BioPAX support to software.
List of data sources & supporting software Databases making data available in BioPAX
format, software systems for storing, visualizing
and analyzing BioPAX pathways.
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Table 3
BioPAX covers five main types of biological pathways and coverage has increased over time with new levels 
of the ontology.
Type of
Biological
Pathway
Main BioPAX Classes Used Introduced
Metabolic
pathways
All types of physical entities (most common use of protein, small
molecule, complex), All types of conversion events (most
common use of BiochemicalReaction, ComplexAssembly and
Transport), Catalysis, Modulation and Pathway
Level 1
Signaling
pathways
All types of physical entities (most common use of protein,
complex), All types of conversion events (most common use of
BiochemicalReaction, ComplexAssembly, Transport and
Degradation), Control, Catalysis, Modulation,
MolecularInteraction, Pathway
Level 2
Molecular
interactions
All types of physical entities (most common use of protein,
complex, small molecule), MolecularInteraction, Pathway
Level 2
Gene
regulatory
networks
All types of physical entities, TemplateReaction,
TemplateReactionRegulation
Level 3
Genetic
interactions
Gene, GeneticInteraction Level 3
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